ABOUT THE PROGRAM
The annual Pharmacogenetics in Psychiatry meeting has provided a forum for the presentation and discussion of new developments in the rapidly developing field of psychiatric pharmacogenetics. Previous meetings have been highlighted by discussion of topics including: prediction of clinical response to antipsychotic drugs, genes associated with the development of adverse side effects, candidate gene and genome-wide association (GWAS) studies of antidepressant response, the identification of new polymorphisms influencing gene product function, and novel statistical approaches to dissect the heterogeneity of drug response. Moreover, we have brought together investigators working in diverse areas of psychiatric research, from molecular geneticists to clinical trial investigators, from academia and industry, in order to engender true interdisciplinary approaches to the problem of variation in clinical response to psychotropic drugs. It is our hope that each participant will come away from this meeting with an appreciation of the breadth of this emerging field.
We would like to thank our financial supporters. These include the Feinstein Institute for Medical Research, the National Institute of Mental Health, and industry partners. Funding for this conference was made possible (in part) by (R13 MH090652) from the National Institute of Mental Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.